Press release
Hyperkalemia Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | AstraZeneca, Vifor Pharma, Zeria Pharma, Ardelyx, Waterstone Pharma
"Hyperkalemia Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/hyperkalemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hyperkalemia Market.
The Hyperkalemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Hyperkalemia Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Hyperkalemia treatment therapies with a considerable amount of success over the years.
*
Hyperkalemia companies working in the treatment market are AstraZeneca, Vifor Pharma/Zeria Pharmaceutical, Ardelyx, Waterstone Pharmaceutical, and others, are developing therapies for the Hyperkalemia treatment
*
Emerging Hyperkalemia therapies in the different phases of clinical trials are- LOKELMA (sodium zirconium cyclosilicate), VELTASSA (patiromer/ZG-801), RDX013, WS016, and others are expected to have a significant impact on the Hyperkalemia market in the coming years.
*
In November 2023, AstraZeneca revealed that its hyperkalemia drug, Lokelma, doubled the chances of continuing lifesaving treatment for patients with heart failure or kidney disease. The UK-based company stated that findings from its real-world, multi-country observational study demonstrated that Lokelma enabled patients on renin-angiotensin-aldosterone system inhibitor (RAASi) therapy to safely continue their treatment.
Hyperkalemia Overview
Hyperkalemia is a medical condition characterized by elevated levels of potassium in the blood. Potassium is essential for normal cell function, especially in nerve and muscle cells, including the heart. However, high potassium levels can disrupt these functions, leading to dangerous complications such as abnormal heart rhythms, muscle weakness, and in severe cases, cardiac arrest. Hyperkalemia is often associated with conditions like chronic kidney disease, diabetes, and heart failure, or can result from certain medications that affect kidney function. Prompt diagnosis and treatment are crucial to prevent life-threatening outcomes.
Get a Free Sample PDF Report to know more about Hyperkalemia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hyperkalemia-pipeline-insight [https://www.delveinsight.com/report-store/hyperkalemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Hyperkalemia Drugs Under Different Phases of Clinical Development Include:
*
LOKELMA (sodium zirconium cyclosilicate): AstraZeneca
*
VELTASSA (patiromer/ZG-801): Vifor Pharma/Zeria Pharmaceutical
*
RDX013: Ardelyx
*
WS016: Waterstone Pharmaceutical
Hyperkalemia Pipeline Therapeutics Assessment
*
Hyperkalemia Assessment by Product Type
*
Hyperkalemia By Stage and Product Type
*
Hyperkalemia Assessment by Route of Administration
*
Hyperkalemia By Stage and Route of Administration
*
Hyperkalemia Assessment by Molecule Type
*
Hyperkalemia by Stage and Molecule Type
DelveInsight's Hyperkalemia Report covers around products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Hyperkalemia product details are provided in the report. Download the Hyperkalemia pipeline report to learn more about the emerging Hyperkalemia therapies [https://www.delveinsight.com/sample-request/hyperkalemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Hyperkalemia Therapeutics Market include:
Key companies developing therapies for Hyperkalemia are - Athira Pharma, Eisai Inc., Eli Lilly and Company, Cognition Therapeutics, EIP Pharma Inc., and others.
Hyperkalemia Pipeline Analysis:
The Hyperkalemia pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Hyperkalemia with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hyperkalemia Treatment.
*
Hyperkalemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Hyperkalemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hyperkalemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Hyperkalemia drugs and therapies [https://www.delveinsight.com/sample-request/hyperkalemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Hyperkalemia Pipeline Market Drivers
*
Increasing Prevalence, Innovative Therapies, Regulatory Support, Growing Awareness, Aging Population, are some of the important factors that are fueling the Hyperkalemia Market.
Hyperkalemia Pipeline Market Barriers
*
However, High Development Costs, Market Competition, Regulatory Challenges, Limited Awareness, Reimbursement Issues, and other factors are creating obstacles in the Hyperkalemia Market growth.
Scope of Hyperkalemia Pipeline Drug Insight
*
Coverage: Global
*
Key Hyperkalemia Companies: AstraZeneca, Vifor Pharma/Zeria Pharmaceutical, Ardelyx, Waterstone Pharmaceutical, and others
*
Key Hyperkalemia Therapies: LOKELMA (sodium zirconium cyclosilicate), VELTASSA (patiromer/ZG-801), RDX013, WS016, and others
*
Hyperkalemia Therapeutic Assessment: Hyperkalemia current marketed and Hyperkalemia emerging therapies
*
Hyperkalemia Market Dynamics: Hyperkalemia market drivers and Hyperkalemia market barriers
Request for Sample PDF Report for Hyperkalemia Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/hyperkalemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Hyperkalemia Report Introduction
2. Hyperkalemia Executive Summary
3. Hyperkalemia Overview
4. Hyperkalemia- Analytical Perspective In-depth Commercial Assessment
5. Hyperkalemia Pipeline Therapeutics
6. Hyperkalemia Late Stage Products (Phase II/III)
7. Hyperkalemia Mid Stage Products (Phase II)
8. Hyperkalemia Early Stage Products (Phase I)
9. Hyperkalemia Preclinical Stage Products
10. Hyperkalemia Therapeutics Assessment
11. Hyperkalemia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Hyperkalemia Key Companies
14. Hyperkalemia Key Products
15. Hyperkalemia Unmet Needs
16 . Hyperkalemia Market Drivers and Barriers
17. Hyperkalemia Future Perspectives and Conclusion
18. Hyperkalemia Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hyperkalemia-pipeline-drugs-analysis-report-2024-updates-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight-astrazeneca-vifor-pharma-zeria-pharma-ardelyx-waterstone-pharma]
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hyperkalemia Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | AstraZeneca, Vifor Pharma, Zeria Pharma, Ardelyx, Waterstone Pharma here
News-ID: 3669422 • Views: …
More Releases from ABNewswire
Hypoparathyroidism Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hypoparathyroidism pipeline constitutes 10+ key companies continuously working towards developing 10+ Hypoparathyroidism treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Hypoparathyroidism Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/hypoparathyroidism-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypoparathyroidism Market.
The Hypoparathyroidism Pipeline report embraces in-depth commercial and clinical…
Acclaimed Novel "Man and Wife" Unholy Matrimony by Andrelle Leandre Available No …
Heartfelt Story Explores the Complexities of Marriage
- Author Andrelle Leandre proudly announces the release of her captivating novel, Man and Wife: Unholy Matrimony . This poignant tale delves into the depths of marriage, exploring the challenges and triumphs that bind couples together.
Leandre's dedication sets the stage for the emotional journey within the novel. It honors her late mother and brother while expressing hope for a brighter future for her son.…
Myelofibrosis Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Comp …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Myelofibrosis pipeline constitutes 45+ key companies continuously working towards developing 45+ Myelofibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Myelofibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Closing The Gender Pay Gap At Swoop
Employer statement on Gender Pay Gap: Swoop Telecommunications
A message from Sherene Shridhar, Chief People Officer:
As the Chief People Officer at Swoop Telecommunications, I take our commitment to gender equality personally. Our recent gender pay gap analysis, showing a median pay gap of 11.8%, has provided us with valuable insights. Compared to the industry comparison group average of 23.5%, it's clear that while we are ahead of the curve, there is…
More Releases for Hyperkalemia
Hyperkalemia Treatment Market 2022-2028 Global Industry Development Trends and A …
The latest Hyperkalemia Treatment Market study offers an all-inclusive analysis of the major strategies, corporate models, and market shares of the most noticeable players in this market. The study offers a thoroughanalysis of the key persuading factors, market figures in terms of revenues, segmental data, regional data, and country-wise data. This study can be described as most wide-ranging documentation that comprises all the aspects of the evolving Hyperkalemia Treatment Market.
Kidneys…
Global Hyperkalemia Supplement Market, Size, Share, Analysis Report & Forecast t …
The global hyperkalemia treatment market is anticipated to grow at a significant CAGR during the forecast period. The major factor for the growth of the market is the increasing chronic diseases such as acute hyperkalemia and chronic hyperkalemia due to other ailments such as diabetes, consumption of high potassium diets, and many other things. As per the National Kidney Foundation, more than 37 million people in the United States have…
Hyperkalemia Treatment Market Technology, Recent Trends, Future Growth Analysis …
Nadroparin is an anticoagulant that belongs to the low molecular weight heparins class of medicines (LMWHs). Nadroparin is used to avoid thromboembolic disorders (deep vein thrombosis and pulmonary embolism) and to treat deep vein thrombosis in general and orthopedic surgery. It's also used to treat unstable angina and non-Q wave myocardial infarction, as well as to prevent clotting during hemodialysis. The global Nadroparin Calcium market size is projected to reach…
Hyperkalemia Therapeutics - Pipeline Analysis 2018 | Ardelyx, Inc., Relypsa
Hyperkalemia is referred to as increased levels of potassium in blood which results in cardiac arrest and death. Potassium levels above 5.1 mEq/l are considered as the hyperkalemia condition.
Download the sample report @ https://www.pharmaproff.com/request-sample/1155
The main causes of hyperkalemia are potassium sifting out of cells into the blood circulation, adrenal gland diseases, kidney dysfunction, uncontrolled diabetes, breakdown of muscle tissue and red blood cells. Hyperkalemia causes abnormal heart rhythms and…
Hyperkalemia Market: Overview, Competitive analysis Market growth and Forecast 2 …
Hyperkalemia Market report offers exhaustive Insight of the pipeline (being worked on) therapeutics situation and development prospects crosswise over Hyperkalemia advancement. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Get Sample PDF of report at:
https://www.marketreportsworld.com/enquiry/request-sample/10919314
Segmentations: -
Hyperkalemia market is segmented on the basis…
Late-Stage Chronic Kidney Disease Induced Hyperparathyroidism, Hyperphosphatemia …
An up-to-date research report has been disclosed by Market Research Hub highlighting the title “OpportunityAnalyzer: Late-Stage Chronic Kidney Disease-Opportunity Analysis and Forecasts to 2026” which focus on three major CKD-induced comorbidities: hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK). The major barrier to CKD market growth over the 2016-2026 forecast period is the loss of patent exclusivity of major drugs in the HPT, HP space. However, the decline in sales will…
